Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BLRX - Bioline Rx Ltd - ADR


Previous close
0.6408
0   0%

Share volume: 167,161
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.64
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 7%
Liquidity 30%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-12.02%
1 Month
-15.03%
3 Months
-21.09%
6 Months
-50.99%
1 Year
-53.46%
2 Year
-57.16%
Key data
Stock price
$0.64
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.51 - $2.53
52 WEEK CHANGE
-$0.68
MARKET CAP 
51.713 M
YIELD 
N/A
SHARES OUTSTANDING 
79.939 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/18/2024
BETA 
1.36
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$206,975
AVERAGE 30 VOLUME 
$255,270
Company detail
CEO: Philip Serlin
Region: US
Website: http://www.biolinerx.com/
Employees: 58
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'​in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain content posted by a third party or links to third party websites (the “content” or “third party content”). this content is provided solely for general informational purposes as a convenience to you and not as an endorsement by the company of the content. it does not constitute a recommendation or solicitation to purchase or sell any security or make any other type of investment or investment decision. the company is not responsible for this content and does not make any representations as to the subject matter, accuracy, completeness or timeliness or the content. if you decide to access linked third party websites, you do so at your own risk. there is no warranty of any kind, express or implied, regarding the content, including without limitation any warranty of m

Recent news